NORTH AMERICA LIVER DISEASE TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-148943 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
North America Liver Disease Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET
7.1 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA NORTH AMERICA LIVER DISEASE TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 ABBVIE INC.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 ASTELLAS PHARMA INC.
16.3 BRISTOL-MYERS SQUIBB COMPANY
16.4 DYNAVAX TECHNOLOGIES CORPORATION
16.5 ELI LILY AND COMPANY
16.6 EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
16.7 GILEAD SCIENCES, INC.
16.8 MERCK & CO. INC.
16.9 MYLAN N.V.
16.10 PFIZER INC. (PHARMACIA CORPORATION)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Treatment TypeAntiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatits
Autoimmune Diseases
Ischemic Stroke
Stenosis
Others
Companies
ABBVIE INC.
ASTELLAS PHARMA INC.
BRISTOL-MYERS SQUIBB COMPANY
DYNAVAX TECHNOLOGIES CORPORATION
ELI LILY AND COMPANY
EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
GILEAD SCIENCES, INC.
MERCK & CO. INC.
MYLAN N.V.
PFIZER INC. (PHARMACIA CORPORATION)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.